American Diabetes Association (ADA) 2026 Scientific Sessions
- Thread starter J Arbey
- Start date
CSM-101
Recently Joined
🚫No Source Discussion🚫
“Women are more prone to UTIs anyway. Is it related to more intercourse
[with weight loss]? Given that this was new, it will now be looked at as we
gather more data,” she added. 😂😂😂😂😂
Adverse Events in Both Trials: A New UTI Signal
In both trials, adverse events were consistent with those seen with other
incretin-based therapies, including nausea in up to 42.4% of patients with
the 12-mg dose in TRIUMPH-1 and up to 26.5% with 12 mg in TRANSCEND-
T2D-1. Other adverse events in both trials included diarrhea, constipation,
and urinary tract infections. Most were mild to moderate and resolved during
treatment.
Urinary tract infections haven’t been seen before, Jastreboff noted. These
occurred mostly in women, in 7.5%-8.8% with retatrutide vs 5.3% with
placebo in TRIUMPH-1 and in 0.7%-2.9% vs 0.0% in TRANSCEND-T2D-1.
“We don’t know, but it may be related to hydration status,” Jastreboff said
during the briefing.
260608
_mscpedit_etid8406950&uac=537876SR&impID=8406950
6/8/26, 17:43
Page 4 of 7
Retatrutide Data Show Dramatic Weight Loss, Other Benefits
“Women are more prone to UTIs anyway. Is it related to more intercourse
[with weight loss]? Given that this was new, it will now be looked at as we
gather more data,” she added.
[with weight loss]? Given that this was new, it will now be looked at as we
gather more data,” she added. 😂😂😂😂😂
Adverse Events in Both Trials: A New UTI Signal
In both trials, adverse events were consistent with those seen with other
incretin-based therapies, including nausea in up to 42.4% of patients with
the 12-mg dose in TRIUMPH-1 and up to 26.5% with 12 mg in TRANSCEND-
T2D-1. Other adverse events in both trials included diarrhea, constipation,
and urinary tract infections. Most were mild to moderate and resolved during
treatment.
Urinary tract infections haven’t been seen before, Jastreboff noted. These
occurred mostly in women, in 7.5%-8.8% with retatrutide vs 5.3% with
placebo in TRIUMPH-1 and in 0.7%-2.9% vs 0.0% in TRANSCEND-T2D-1.
“We don’t know, but it may be related to hydration status,” Jastreboff said
during the briefing.
260608
_mscpedit_etid8406950&uac=537876SR&impID=8406950
6/8/26, 17:43
Page 4 of 7
Retatrutide Data Show Dramatic Weight Loss, Other Benefits
“Women are more prone to UTIs anyway. Is it related to more intercourse
[with weight loss]? Given that this was new, it will now be looked at as we
gather more data,” she added.
